STUDresearch · Non-peptide
TA-65
Also known as
TA65 · TA-65MD · TA-65 MD · cycloastragenol (related active / class discussion) · TAT2 (research synonym in older literature) · Astragalus root extract (branded telomerase-activator product) · telomerase activator 65 · T.A. Sciences TA-65 · CAG (cycloastragenol shorthand in literature)
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Niche talk
Systemic
Oral
Longevity & cellular energy
Systemic oral telomerase-pathway supplement (branded cycloastragenol-class capsule); whole-body longevity and immune-aging talk.
What people say
A branded oral Astragalus-derived cycloastragenol-class supplement marketed around telomerase and aging biomarkers. It is not an FDA-approved anti-aging drug.
Doses people talk about
Units are not generic international units, and branded TA-65 is not automatically equivalent to generic cycloastragenol or Astragalus extracts.
How it may feel
The evidence story is biomarker-focused, not an acute sensation. Accounts conflict: one author said an earlier strength impression disappeared after about six months; one reported vivid dreams; another reported no dream change despite 6–8 capsules daily.
Year-long telomere-study arm250 U once daily (about 8 mg active)
Morning oral arm in the preserved trial description; 1000 U/day was a separate arm.
Metabolic-syndrome studyAbout 8 mg twice daily (16 mg/day)
Two oral pills daily for 12 weeks in a crossover design with washout.
Post-MI pilot8 mg twice daily (16 mg/day)
Oral pilot amount reported for 12 months; a medical-study context, not longevity advice.
Half-life & effect duration
- Half-life in the body
- Branded oral TA-65No settled estimate
- Cycloastragenol · oral · ratsAbout 5–7 hours
- Felt duration people report
- Dream reportsVivid dreams or no change
- Longer accountEarlier strength effect absent by about 6 months
Cycles people discuss
Commercial use is often continuous, while trials used continuous blocks or a 90-days-on/14-days-off repeating schedule. These designs do not prove a required cycle.
Timing
Morning empty-stomach use appears in product and study instructions. Continuous daily blocks and a 90-days-on/14-days-off study schedule both appear; neither establishes a required biological cycle.
Stacks
TA-65 appears beside NAD precursors, Epitalon and other longevity products, but co-use makes subjective and biomarker attribution weaker and does not establish synergy.
Watch for
Cancer theory (core caution): Telomerase is active in many cancers; theoretical risk of promoting existing malignancy drives clinician caution even when short animal studies and ~12-month human windows report no incidence rise.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
A route-specific human plasma half-life for branded TA-65 was not established by the inspected sources.
A recent review reports rat oral cycloastragenol pharmacokinetics, including about 5.23 hours at 10 mg/kg, but that is a different species and cannot be converted into branded Unit timing.
Branded formulation, proprietary Units, generic cycloastragenol and plant extracts are not interchangeable. Rat kinetics do not supply human TA-65 clearance.
- Cycloastragenol pharmacology and pharmacokinetics review (opens in a new tab)Pharmacokinetics section reporting rat oral cycloastragenol Tmax 2.06 hours, half-life 5.23 hours and 25.7% bioavailability at 10 mg/kg, with citations to the underlying animal work.Recent secondary review of animal CAG data; not branded TA-65 human PK and not evidence that Units equal a generic milligram amount.
Felt duration people report
No dependable felt-duration clock; accounts include vivid dreams, no perceived dream change, or effects changing across months.
One author said an earlier strength effect was absent after about six months amid anemia and other products. Another reported vivid dreams during intermittent low-amount use and no perceived food/timing absorption difference; a different poster reported no dream change at 6–8 capsules daily for a few months.
Uncontrolled self-reports, different products and extensive health or supplement confounding; no verified objective causal attribution.
- TA-65 follow-up in Epitalon discussion (opens in a new tab)July 2014 Gramson post: reported prior strength gains with TA-65 and no remaining effect after about six months; same post describes anemia, iron treatment and concurrent Reneuve context.Retrospective uncontrolled report with changing health and multiple products; no verified dose, assay or causal attribution.
- Long-term TA-65 discussion (opens in a new tab)August 2013 discussion: free10 described use since early 2011 with months off, usually low amounts/every other day, vivid realistic dreams and no perceived food/timing absorption difference; piet3r separately reported 6–8 capsules daily for a few months with no dream change and little dream recall.Different uncontrolled authors, unverified products and subjective observations; no plasma measurements, controlled food/timing comparison or comparable exposure verification.
What people say
- Feel / vigor: Longevity users sometimes report subtle energy, recovery, or “less aged” narratives over months—highly confounded by stacks, sleep, and expectation; many report no acute feel. forum
- Skin product line: Separate topical TA-65 for Skin cream is marketed for wrinkles / prematurely aged skin appearance; oral-systemic data do not automatically transfer. forum
- Vs generic cycloastragenol: Brand claims proprietary MD formulation bioavailability advantages (vendor “many-fold / up to ~50×” marketing appears in reseller writeups); independent head-to-head human equivalence is not community consensus. forum
- Vs Epitalon: Oral small-molecule / branded supplement vs injectable synthetic pineal tetrapeptide research class; both sit in “telomerase / telomere” search space; no head-to-head human longevity RCTs. forum
- Telomere RCT (year-long DBPC, CMV+ adults): Low-dose TA-65 250 U/day significantly lengthened median telomeres (~+530 ± 180 bp over 12 months) while placebo lost length (~−290 ± 100 bp); high-dose 1000 U showed only a non-significant trend vs placebo. trial
- Bell-curve dose talk: Same RCT and later commentary raise a possible bell-shaped dose-response (formulated 250 U / ~8 mg worked; 1000 U / ~32 mg did not reach significance; earlier unformulated ~5–10 mg observational use had no clear TL change). trial
- Immune / immunosenescence RCT (~500 subjects, 9 months): Oral TA-65 arms (100 U qd, 250 U qd, 500 U qd, 250 U bid) reduced CD8+CD28− senescent T cells vs placebo; lower doses (~100–250 U) showed numerically larger decrements (~28 cells/μl) than 500 U (~22 cells/μl) in reported analyses. trial
- Metabolic syndrome crossover: ~16 mg/day TA-65 (two ~8 mg pills) for 12 weeks vs placebo periods: higher HDL-C, lower BMI, waist circumference, LDL/HDL ratio, and lower TNF-α; HDL changes correlated with inflammatory-marker improvements. trial
- Post-MI pilot (elderly, 12 months): TA-65 ~16 mg/day (8 mg bid) did not change primary CD8+ TEMRA proportion vs placebo, but increased total lymphocytes (CD3+/CD4+/CD8+, B cells, NK) and reduced hsCRP (~62% lower at 12 months in reported comparison); fewer total adverse events in active arm. trial
- Meta-analytic telomere signal: Systematic review/meta of multiple RCTs reports moderate pooled telomere elongation (example pooled SMD ~0.47), larger in adults >60, with industry-funded trials showing larger effect sizes than non-industry; telomere gains did not clearly translate to frailty or CRP/IL-6 functional improvements. trial
- In-vitro immune: Earlier TAT2/TA-65 work on CD8+ T cells reported increased telomerase activity and improved replicative capacity in culture. lab
- Animal healthspan: Mouse work (e.g., de Jesus et al.): elongated short telomeres, improved some healthspan markers (glucose, bone, skin narratives cited), without clear increase in cancer incidence; normal-mouse lifespan not clearly extended. animal
- What is not proven: Human life extension, broad DNA-repair claims, cancer-risk reduction, or reliable reversal of clinical aging phenotypes beyond selected biomarkers. trial
Doses people talk about
- Commercial capsule strengths: Common retail SKUs are 100 Units and 250 Units per capsule (30- or 90-count bottles discussed); “Units” are brand-proprietary, not USP international units of a different drug. forum
- Generic cycloastragenol charts: Supplement vendors and review sites commonly discuss ~10–50 mg/day oral cycloastragenol for ~3–6 months (or longer maintenance); identity and potency vs branded Units are not guaranteed equivalent. forum
- Product / clinic daily use talk: Once-daily capsules are the default commercial pattern; some clinic writeups scale capsule count by age/health (e.g., ~1–2 caps prevention talk in younger healthy adults vs ~3–6 caps in older or chronically ill narratives)—these are clinic marketing schedules, not RCT arms. forum
- Unit ↔ mg map (trial text): TA-65MD 250 U capsule described as containing ~8 mg active ingredient; 1000 U = four 250 U capsules ≈ ~32 mg active in the same formulation family. trial
- Trial high dose (trend only): 1000 U/day (four 250 U capsules) studied in the same year-long trial; TL vs placebo did not reach statistical significance. trial
- MetS trial dose: ~16 mg/day total as two ~8 mg pills for 12 weeks (crossover with washout). trial
- Post-MI pilot dose: 8 mg twice daily (16 mg/day) for 12 months. trial
- Meta-analysis dose band: Reviewed human TA-65/class dosing often summarized ~10–50 mg/day over ~6–24 months; no clear linear dose–response for telomere effect within that band in the pooled analysis. trial
- Observational unformulated note: Very low ~5–10 mg/day unformulated active (pre-MD bioavailability push) reported no significant TL change—used to argue formulation and dose shape matter. trial
- Empty stomach: Morning dosing away from food is the dominant product/clinic and year-long trial instruction. trial
- Framing: Trial, product-label, clinic, and community discussion ranges only—not advice, not a protocol, not FDA-labeled drug dosing. forum
- Trial low dose with significant TL lengthening: 250 U oral once daily (morning, empty stomach) in the year-long DBPC telomere study. trial
- Immune RCT arms (9 months): Placebo vs 100 U qd, 250 U qd, 500 U qd, or 250 U bid; all subjects took two capsules/day (active + placebo as needed for blinding), morning and evening. trial
- Related blend example (not TA-65): Separate Astragalus complexes (e.g., products providing ~25 mg cycloastragenol plus astragaloside IV and polyphenols twice daily) appear in non-TA-65 RCTs—do not treat as TA-65 Unit math. trial
- More is not clearly better: Both the year-long TL RCT (250 U > 1000 U on significance) and the immune RCT (lower Units numerically stronger on CD8+CD28−) fuel “don’t blindly max dose” community talk. trial
How it may feel
- Days 1–14 and longer: Acute stimulant-like effects are not established by the biomarker-oriented story. One forum author described earlier strength gains on TA-65 but said the effect had disappeared after about six months; anemia, iron treatment and other products were important confounders. Another long-term user reported vivid realistic dreams during intermittent low-amount use, while a different poster taking 6–8 capsules daily for a few months reported no dream change and rarely remembering dreams. anecdote
- Weeks 3–8: Energy/recovery anecdotes, if any, build slowly and are hard to isolate from concurrent NAD, sleep, or training changes. forum
- Months 3–6: Common first window for telomere assay curiosity or immune-lab rechecks; assay noise and lab-method differences (qPCR vs Southern vs flow-FISH) dominate interpretation debates. forum
- No change ~3–6 mo: Cost, brand vs generic identity, empty-stomach compliance, assay choice, and “wrong goal” (expecting visible youth vs biomarker shift) are common rechecks. forum
- Months 6–9: Aligns with the large immunosenescence RCT endpoint (CD8+CD28− shifts reported at ~9 months). trial
- Months 9–12: Primary telomere RCT judgment window (significant median TL change at 9 and 12 months for 250 U in the year-long trial; 6-month signal was weaker/non-significant in that study). trial
- Beyond 12 months: Maintenance habit talk; meta commentary often frames telomere gains as plateauing rather than endless linear lengthening. trial
Cycles people discuss
- Daily continuous (commercial default): Most consumer and clinic talk is open-ended daily oral use, not short bodybuilding-style bursts. forum
- Long maintenance: Past one year framed as chronic low-intensity longevity support if users continue; long-term cancer and functional-outcome data remain limited. forum
- Generic cycloastragenol cycles: Some vendor/review language suggests multi-month on periods (e.g., ~3–6 months) then reassessment—varies widely. forum
- Trial pulsed schedule (telomere RCT): ~90 days on product / ~14 days off, repeating in 104-day cycles across ~1 year. trial
- Continuous trial schedules: Immune RCT used ~9 months continuous dual-capsule dosing; MetS used 12-week blocks; post-MI pilot used 12 months continuous. trial
- Judge at 6–12 months: Common horizon for telomere labs, immune markers, and cost/benefit decisions; meta commentary often cites early plateau rather than multi-year linear gains. trial
Timing
- Formulation bioavailability fight: TA-65MD is marketed as enteric-coated / proprietary delivery to raise absorption vs plain plant extract or generic CAG; reseller claims of large fold-increases (including “up to ~50×”) circulate—treat as vendor marketing, not independent RCT endpoints. forum
- Lab lag: Telomere and immune shifts are judged at months; short-term subjective “feel” is a poor surrogate. forum
- Human branded PK gap: Clear public human plasma half-life tables for commercial TA-65MD are not what consumer dosing charts primarily use; schedule is driven by trial design and product habit, not a published depot half-life. trial
- Rat cycloastragenol PK (class molecule): Oral CAG studies report moderate absorption; elimination half-life on the order of ~5–7 hours across ~10–40 mg/kg rat doses; oral bioavailability cited ~25.7% at 10 mg/kg in one PK paper. animal
- First-pass / metabolism: CAG literature discusses intestinal absorption plus extensive hepatic metabolism; astragaloside IV (related Astragalus saponin) has much lower oral bioavailability than CAG in comparative PK writeups. animal
- Daily oral timing: Once daily (morning empty stomach) or twice daily (immune RCT / MI pilot style) capsules—not weekly injectable logic. trial
- Plateau talk: Lengthening or marker shifts often discussed as 6–12 month windows rather than endless linear gains with dose or time. trial
More on what it is
- IP lineage: Cycloastragenol was associated with Geron Corporation patents and later commercialized via Telomerase Activation Sciences (TA Sciences). forum
- Why people care: One of the few commercial telomere products with named human double-blind RCTs on telomere length and immunosenescence markers; high price and FTC history keep it in longevity debates. forum
- What it is: Branded oral Astragalus-derived small-molecule telomerase activator sold as TA-65 / TA-65MD (T.A. Sciences); marketed as a purified single chemical entity in the cycloastragenol class, as a dietary supplement / medical-food-framed product—not an FDA-approved drug. trial
- History name: Older research literature sometimes used TAT2 for the same activator class before commercial TA-65 branding. trial
- Mechanism talk: Modest, transient TERT/telomerase activation; preferential discussion of short telomeres, CD8+ senescent T-cell burden, and immune-aging narratives rather than “immortality.” trial
- Unit vs mg: Commercial capsules are labeled in proprietary “Units” (commonly 100 U or 250 U per cap); trial text maps ~250 U to ~8 mg active and ~1000 U to ~32 mg active in the TA-65MD formulation—Units are not interchangeable with random generic mg labels. trial
- Evidence honesty: Small–moderate human RCTs report telomere or immune-marker shifts; human lifespan extension is unproven; a 2025 meta-analysis reported moderate telomere elongation without clear frailty/inflammation functional gains. trial
- Not this: Not a peptide, not Epitalon, not a steroid/SARM, not crude whole Astragalus tea milligram-for-milligram, and not proven aging reversal or DNA-repair therapy. trial
Stacks
- NAD axis: Frequently listed next to NMN, NR, or NAD+ IV/oral—shared longevity aisle, not a co-formulated proven synergy RCT. forum
- Epitalon / pineal peptides: Some alternate or rotate oral TA-65-class use with Epitalon (or epithalamin) courses; injectable vs oral and different evidence bases; no head-to-head stack RCT. forum
- Autophagy / senolytic neighbors: Spermidine, fisetin, quercetin-class healthspan stacks commonly share the same shopping cart. forum
- mTOR / metabolic longevity: Sometimes discussed alongside metformin or rapamycin interest—high confound and different risk profiles. forum
- Astragalus polyphenol blends: Non-TA-65 products combining cycloastragenol + astragaloside IV + olive/grape extracts appear in separate trials; users may stack or substitute without Unit math. forum
- Antioxidant / mitochondrial: CoQ10, PQQ, or multi-antioxidant longevity stacks appear in forum lists. forum
- Lifestyle always credited: Sleep, resistance training, inflammation control, and CMV/infection burden discussions sit next to any telomere claim. forum
- Avoid double-counting: Stacking branded TA-65 with high-dose generic cycloastragenol without accounting for total active load is a common identity/math risk. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Cancer theory (core caution): Telomerase is active in many cancers; theoretical risk of promoting existing malignancy drives clinician caution even when short animal studies and ~12-month human windows report no incidence rise. forum
- FTC history (2018): U.S. FTC settled deceptive-advertising charges against Telomerase Activation Sciences / Noel Patton over broad anti-aging, DNA-repair, immune-restore, and related claims for TA-65MD and TA-65 for Skin; final consent order requires competent scientific support for health claims and bars misrepresenting paid ads as independent programming. forum
- Cost / opportunity cost: Retail often hundreds of dollars per bottle (e.g., 100 U ~30-count and 250 U multi-bottle pricing in the hundreds); cost alone drives “is the biomarker worth it?” debates independent of molecular risk. forum
- Identity / potency risk: Generic cycloastragenol mg, crude Astragalus extracts, and branded Units are not interchangeable; purity and label accuracy vary outside cGMP brand channels. forum
- Pregnancy / pediatric: Not a researched use case in the adult longevity literature; community treats as avoid-by-default. forum
- Drug interaction data gap: Formal interaction tables are sparse; polypharmacy longevity stacks remain under-characterized. forum
- GI (most cited): Mild nausea and abdominal discomfort dominate human AE lists; one meta safety summary reported ~12.4% treatment-emergent GI-type events (nausea ~7.1%, abdominal discomfort ~5.3%) with mild–moderate severity and no severe oncogenesis events across ~12-month median follow-ups in pooled safety n. trial
- Trial AE rates: Large immune RCT reported mild–moderate AEs in ~34.6% of subjects overall; serious AEs occurred but were not deemed related (or were unlikely related) to product in that writeup. trial
- Post-MI pilot AE signal: Active arm reported fewer total adverse events than placebo in that pilot—still not a general safety proof for all populations. trial
- Animal cancer data: Mouse healthspan/telomere work and a UV-skin-cancer model reported no statistically significant increase in tumor incidence with TA-65—supportive but not human lifetime proof. animal
- Cancer history: Active or recent malignancy is treated as high-stakes clinician territory, not casual biohacking, in community and clinic framing. forum
- Industry-bias note: Meta-analysis commentary that industry-funded trials reported larger telomere effect sizes than non-industry work is part of evidence-honesty talk. trial
- Telomere–function disconnect: Pooled analyses finding telomere elongation without clear frailty or inflammatory-marker functional gains undercut “longer telomeres = younger you” marketing. trial
- Not risk-free: Absence of short-term SAEs in selected trials ≠ lifelong safety, youth benefit, or zero theoretical oncogenic risk. trial
Evidence mix
More trial/lab tags than forum tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.